Analyst consensus rating
AstraZeneca Analyst Rating: Strong Buy
AZN is rated Strong Buy by 11 analysts with a $212.54 target. As of 2026-09-02.
Direct answer
AstraZeneca's consensus rating is Strong Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $212.54.
Forecast evidence checked September 2, 2026.
Get free AstraZeneca email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $162.47
- Average price target
- $212.54
- High price target
- $240.00
- Low price target
- $184.00
- Low target gap
- +13.3%
- Target upside
- +30.8%
- High target gap
- +47.7%
- Target range width
- 34.5%
- Consensus rating
- Strong Buy
- Analysts
- 11
- Evidence date
- September 2, 2026
- Valid through
- September 9, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for AstraZeneca?
AstraZeneca has a verified Strong Buy consensus. The same dataset has an average price target of $212.54.
How far are AstraZeneca's low and high targets from the recorded price?
The low target implies +13.3%, while the high target implies +47.7%.
How many analysts are included in AstraZeneca's consensus?
The verified consensus includes 11 analysts.
How is AstraZeneca's target upside or downside calculated?
The average target of $212.54 is divided by the recorded price of $162.47, then one is subtracted to produce +30.8%. This does not guarantee a future return.
When was AstraZeneca's analyst forecast verified?
The data was verified on 2026-09-02. The dataset is valid through 2026-09-09.